Inspire Medical Systems (2DR) Stock Forecast & Price Target

11 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

2DR Analyst Ratings

Hold

3 Buy

9 Hold

2 Sell

Based on 14 analysts giving stock ratings to

Inspire

Medical Systems

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

2DR Stock 12 Month Forecast

Average Price Target

€44.99

▲(2.25% Upside)

Based on 14 Wall Street analysts offering 12 month price targets for Inspire Medical Systems in the last 3 months. The average price target is €44.99 with a high forecast of €57.15 and a low forecast of €34.29. The average price target represents a 2.25% change from the last price of €44.00.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"33":"€33","52":"€52","71":"€71","90":"€90","109":"€109"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":57.1512981,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€57.15</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":44.98832953000001,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€44.99</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":34.29077886,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€34.29</span>\n  </div></div>","useHTML":true}}],"tickPositions":[33,52,71,90,109],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2025","6":"Jan<br/>2026","9":"Apr<br/>2026","12":"Jul<br/>2026","25":"Jul<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,39.6,40.950099853846154,42.30019970769231,43.65029956153846,45.000399415384614,46.35049926923077,47.70059912307693,49.05069897692307,50.40079883076923,51.75089868461538,53.10099853846154,54.45109839230769,55.801198246153845,{"y":57.1512981,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,39.6,40.01448688692308,40.42897377384616,40.84346066076923,41.25794754769231,41.67243443461539,42.08692132153847,42.50140820846154,42.91589509538462,43.3303819823077,43.74486886923078,44.15935575615385,44.57384264307693,{"y":44.98832953000001,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,39.6,39.191598373846155,38.78319674769231,38.37479512153846,37.966393495384615,37.55799186923077,37.14959024307693,36.74118861692308,36.332786990769236,35.92438536461539,35.51598373846154,35.107582112307696,34.69918048615385,{"y":34.29077886,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":108.45,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":105.7,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":78.82,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":60.86,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":61.5,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":106.7,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":78.32,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":62.12,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":53.82,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":42.77,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":45.4,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":35.8,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":39.6,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target€57.15

Average Price Target€44.99

Lowest Price Target€34.29

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Patrick Wood

UBS

€58.91→€34.29

Sell

-22.07%

Downside

Downgraded

07/28/26

Richard Newitter

Truist Financial

€43.96→€47.48

Hold

7.91%

Upside

Reiterated

07/16/26

Inspire Medical price target raised to $54 from $50 at TruistInspire Medical price target raised to $54 from $50 at Truist

Shagun Singh Chadha

RBC Capital

€39.57

Hold

-10.08%

Downside

Reiterated

07/13/26

RBC Capital Reaffirms Their Hold Rating on Inspire Medical Systems (INSP)

Larry Biegelsen

Wells Fargo

€49.24

Hold

11.90%

Upside

Reiterated

07/02/26

Inspire Medical Systems (INSP) Gets a Hold from Wells Fargo

Keith Hinton

Freedom Capital Markets

€54.51

Buy

23.89%

Upside

Initiated

06/30/26

Analysts Are Bullish on Top Healthcare Stocks: MindWalk Holdings (HYFT), AnaptysBio (ANAB)

Daniel Markowitz CFA

Evercore ISI

€48.36→€35.17

Hold

-20.07%

Downside

Downgraded

06/23/26

Inspire Medical downgraded to In Line from Outperform at Evercore ISIInspire Medical downgraded to In Line from Outperform at Evercore ISI

Travis Steed

Bank of America Securities

€46.6→€34.29

Sell

-22.07%

Downside

Downgraded

05/22/26

Inspire Medical downgraded to Underperform from Neutral at BofAInspire Medical downgraded to Underperform from Neutral at BofA

Suraj Kalia

Oppenheimer

―

Hold

―

Reiterated

05/07/26

Oppenheimer sees new MAC billing change as fresh headache for Inspire MedicalOppenheimer sees new MAC billing change as fresh headache for Inspire Medical

Adam Maeder

Piper Sandler

€74.74→€48.36

Hold

9.91%

Upside

Downgraded

05/05/26

Inspire Medical downgraded to Neutral from Overweight at Piper SandlerInspire Medical downgraded to Neutral from Overweight at Piper Sandler

Anthony Petrone

Mizuho Securities

€61.55→€48.36

Buy

9.91%

Upside

Reiterated

05/05/26

Inspire Medical price target lowered to $55 from $70 at MizuhoInspire Medical price target lowered to $55 from $70 at Mizuho

Robbie Marcus

J.P. Morgan

€58.91→€47.48

Hold

7.91%

Upside

Reiterated

05/05/26

Inspire Medical price target lowered to $54 from $67 at JPMorganInspire Medical price target lowered to $54 from $67 at JPMorgan

Jonathan Block

Stifel Nicolaus

€61.55→€57.15

Buy

29.89%

Upside

Reiterated

05/05/26

Stifel Nicolaus Reaffirms Their Buy Rating on Inspire Medical Systems (INSP)

David Rescott

Robert W. Baird

€55.39→€43.96

Hold

-0.09%

Downside

Reiterated

05/05/26

Inspire Medical price target lowered to $50 from $63 at BairdInspire Medical price target lowered to $50 from $63 at Baird

Brett Fishbin

KeyBanc

―

Hold

―

Reiterated

05/05/26

Analysts' Opinions Are Mixed on These Healthcare Stocks: Xencor (NASDAQ: XNCR), Inspire Medical Systems (NYSE: INSP) and Amgen (NASDAQ: AMGN)

Michael Polark

Wolfe Research

―

Hold

―

Downgraded

02/13/26

Inspire Medical downgraded to Peer Perform from Outperform at Wolfe ResearchInspire Medical downgraded to Peer Perform from Outperform at Wolfe Research

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Patrick Wood

UBS

€58.91→€34.29

Sell

-22.07%

Downside

Downgraded

07/28/26

Richard Newitter

Truist Financial

€43.96→€47.48

Hold

7.91%

Upside

Reiterated

07/16/26

Inspire Medical price target raised to $54 from $50 at TruistInspire Medical price target raised to $54 from $50 at Truist

Shagun Singh Chadha

RBC Capital

€39.57

Hold

-10.08%

Downside

Reiterated

07/13/26

RBC Capital Reaffirms Their Hold Rating on Inspire Medical Systems (INSP)

Larry Biegelsen

Wells Fargo

€49.24

Hold

11.90%

Upside

Reiterated

07/02/26

Inspire Medical Systems (INSP) Gets a Hold from Wells Fargo

Keith Hinton

Freedom Capital Markets

€54.51

Buy

23.89%

Upside

Initiated

06/30/26

Analysts Are Bullish on Top Healthcare Stocks: MindWalk Holdings (HYFT), AnaptysBio (ANAB)

Daniel Markowitz CFA

Evercore ISI

€48.36→€35.17

Hold

-20.07%

Downside

Downgraded

06/23/26

Inspire Medical downgraded to In Line from Outperform at Evercore ISIInspire Medical downgraded to In Line from Outperform at Evercore ISI

Travis Steed

Bank of America Securities

€46.6→€34.29

Sell

-22.07%

Downside

Downgraded

05/22/26

Inspire Medical downgraded to Underperform from Neutral at BofAInspire Medical downgraded to Underperform from Neutral at BofA

Suraj Kalia

Oppenheimer

―

Hold

―

Reiterated

05/07/26

Oppenheimer sees new MAC billing change as fresh headache for Inspire MedicalOppenheimer sees new MAC billing change as fresh headache for Inspire Medical

Adam Maeder

Piper Sandler

€74.74→€48.36

Hold

9.91%

Upside

Downgraded

05/05/26

Inspire Medical downgraded to Neutral from Overweight at Piper SandlerInspire Medical downgraded to Neutral from Overweight at Piper Sandler

Anthony Petrone

Mizuho Securities

€61.55→€48.36

Buy

9.91%

Upside

Reiterated

05/05/26

Inspire Medical price target lowered to $55 from $70 at MizuhoInspire Medical price target lowered to $55 from $70 at Mizuho

Robbie Marcus

J.P. Morgan

€58.91→€47.48

Hold

7.91%

Upside

Reiterated

05/05/26

Inspire Medical price target lowered to $54 from $67 at JPMorganInspire Medical price target lowered to $54 from $67 at JPMorgan

Jonathan Block

Stifel Nicolaus

€61.55→€57.15

Buy

29.89%

Upside

Reiterated

05/05/26

Stifel Nicolaus Reaffirms Their Buy Rating on Inspire Medical Systems (INSP)

David Rescott

Robert W. Baird

€55.39→€43.96

Hold

-0.09%

Downside

Reiterated

05/05/26

Inspire Medical price target lowered to $50 from $63 at BairdInspire Medical price target lowered to $50 from $63 at Baird

Brett Fishbin

KeyBanc

―

Hold

―

Reiterated

05/05/26

Analysts' Opinions Are Mixed on These Healthcare Stocks: Xencor (NASDAQ: XNCR), Inspire Medical Systems (NYSE: INSP) and Amgen (NASDAQ: AMGN)

Michael Polark

Wolfe Research

―

Hold

―

Downgraded

02/13/26

Inspire Medical downgraded to Peer Perform from Outperform at Wolfe ResearchInspire Medical downgraded to Peer Perform from Outperform at Wolfe Research

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

AVBPArriVent BioPharma, Inc.

BTSGBrightSpring Health Services, Inc.

MLYSMineralys Therapeutics, Inc.

AMLXAmylyx Pharmaceuticals Inc

ZURAZura Bio

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Inspire Medical Systems

3 Months

Frank TakkinenLake Street

Success Rate

11/20 ratings generated profit

Average Return

+5.56%

Copying Frank Takkinen's trades and holding each position for 3 Months would result in 55.00% of your transactions generating a profit, with an average return of +5.56% per trade.

1 Year

Jonathan BlockStifel Nicolaus

Success Rate

12/22 ratings generated profit

Average Return

+27.06%

Copying Jonathan Block's trades and holding each position for 1 Year would result in 54.55% of your transactions generating a profit, with an average return of +27.06% per trade.

2 Years

Jonathan BlockStifel Nicolaus

Success Rate

12/22 ratings generated profit

Average Return

+55.17%

Copying Jonathan Block's trades and holding each position for 2 Years would result in 54.55% of your transactions generating a profit, with an average return of +55.17% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

2DR Analyst Recommendation Trends

Rating

Mar 26

Apr 26

May 26

Jun 26

Jul 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, 2DR has received 4 Buy Ratings, 15 Hold Ratings, and 3 Sell Ratings. 2DR average Analyst price target in the past 3 months is 44.99.

Each month's total comprises the sum of three months' worth of ratings.

2DR Financial Forecast

2DR Earnings Forecast

Next quarter’s earnings estimate for 2DR is -€0.20 with a range of -€0.33 to -€0.13. The previous quarter’s EPS was €0.09. 2DR beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 40.24% of the time in the same period. In the last calendar year 2DR has Performed in-line its overall industry.

2DR Sales Forecast

Next quarter’s sales forecast for 2DR is €168.79M with a range of €167.47M to €170.76M. The previous quarter’s sales results were €177.33M. 2DR beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 44.19% of the time in the same period. In the last calendar year 2DR has Performed in-line its overall industry.

2DR Stock Forecast FAQ

What is DE:2DR’s average 12-month price target, according to analysts?

Based on analyst ratings, Inspire Medical’s 12-month average price target is 44.99.

What is DE:2DR’s upside potential, based on the analysts’ average price target?

Inspire Medical has 2.25% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Inspire Medical a Buy, Sell or Hold?

Inspire Medical has a consensus rating of Hold, which is based on 3 buy ratings, 9 hold ratings and 2 sell ratings.

What is Inspire Medical’s share price target?

The average share price target for Inspire Medical is 44.99. This is based on 14 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is €57.15 ,and the lowest forecast is €34.29. The average share price target represents 2.25% Increase from the current price of €44.

What do analysts say about Inspire Medical?

Inspire Medical’s analyst rating consensus is a Hold. This is based on the ratings of 14 Wall Streets Analysts.

How can I buy shares of Inspire Medical?

To buy shares of DE:2DR, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Inspire Medical Systems (2DR) Stock Forecast & Price Target

2DR Analyst Ratings

2DR Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Inspire Medical Systems

2DR Analyst Recommendation Trends

2DR Financial Forecast

2DR Earnings Forecast

2DR Sales Forecast

2DR Stock Forecast FAQ

Detailed List of Analyst Forecasts